 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Drug resistance of group B Streptococus (Streptococcus agalactiae) |
| Language |
J |
| AuthorList |
Kouji Kimura |
| Affiliation |
Department of Bacteriology, Nagoya University Graduate School of Medicine |
| Publication |
J.J.C.M.: 29 (4), 183-195, 2019 |
| Received |
May 20, 2019 |
| Accepted |
|
| Abstract |
Group B Streptococcus, GBS, Streptococcus agalactiae, is the leading cause of neonatal sepsis and meningitis. Moreover, it can cause invasive diseases against non-pregnant adults, especially the elderly and diabetes patients et al. Because all clinical isolates of GBS were uniformly susceptible to beta-lactams, the first-line agents of prevention and treatment against GBS infections are beta-lactams. Recently, from many countries including Japan, group B Streptococcus with reduced beta-lactam susceptibility, GBS-RBS, which harbor altered penicillin-binding proteins, PBPs, the target molecules of beta-lactams, were reported. GBS-RBS, especially group B Streptococcus with reduced penicillin susceptibility, PRGBS, which are non-susceptible to the first-line agent, penicillin, are also resistant both to macrolides and fluoroqinolones and show the tendency of multi-drug resistance. In this review, I describe the drug resistance of GBS with a focus on beta-lactam non-susceptibility and drug susceptibilities to other drugs including relatively new drugs. |
| Keywords |
Streptococcus agalactiae, GBS |
|
